Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.

We evaluated the safety and efficacy of exisulind for delaying disease progression in men with increasing prostate specific antigen (PSA) after radical prostatectomy.
A total of 96 men with increasing PSA after radical prostatectomy were randomized to receive placebo (49) or 250 mg. exisulind twice daily (47) for 12 months. The primary efficacy parameter was the difference in change from baseline PSA between the placebo and exisulind groups. The PSA doubling time was also evaluated before and during study. A subgroup analysis classified patients based on the risk of developing metastatic disease.
Compared with placebo, exisulind significantly suppressed the increase in PSA in all patients (p = 0.017). The results were also statistically significant in men at high risk for metastasis (p = 0.0003) and those who could not be classified according to risk (p = 0.0009). In addition, median PSA doubling time was lengthened in high risk patients on exisulind (2.12 month increase) compared with those on placebo (3.37 month decrease, p = 0.048). Exisulind was well tolerated.
Exisulind inhibited the increase in PSA overall and prolonged PSA doubling time in high risk patients compared with placebo. These results suggest that Exisulind has the potential to extend the time from biochemical recurrence to the need for androgen deprivation therapy. Exisulind was well tolerated in this patient population. Our results support further study of Exisulind in the treatment of patients with prostate cancer.
AuthorsE T Goluboff, D Prager, D Rukstalis, B Giantonio, M Madorsky, I Barken, I B Weinstein, A W Partin, C A Olsson,
JournalThe Journal of urology (J Urol) Vol. 166 Issue 3 Pg. 882-6 (Sep 2001) ISSN: 0022-5347 [Print] United States
PMID11490238 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Sulindac
  • Prostate-Specific Antigen
  • sulindac sulfone
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Combined Modality Therapy
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (blood, drug therapy)
  • Postoperative Complications (epidemiology)
  • Prostate-Specific Antigen (blood)
  • Prostatectomy
  • Prostatic Neoplasms (blood, drug therapy, surgery)
  • Sulindac (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: